European approval for Guidant's heart device:
This article was originally published in Clinica
Executive Summary
Guidant has CE-marked for sale in Europe its latest cardiac resynchronisation therapy defibrillator (CRT-D), the Contak Renewal 4. Claimed to be the thinnest CRT-D available, the implantable device contains additional enhancements on previous Renewal versions, including a high energy option for larger hearts that require more power to restore normal rhythm and HRV Monitor Footprint technology. This which allows visualisation of patient heart rate over time. Like previous versions, the device contains diagnostic sensing for customised therapy to the left and right ventricles. The firm announced that the first implantations of the Renewal 4 have taken place in Italy and Germany.